Synonyms: IMP-4297 | IMP4297
Compound class:
Synthetic organic
Comment: Senaparib (IMP4297) is an oral PARP1 inhibitor that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [1].
|
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | Phase 1 Interventional | Impact Therapeutics, Inc. | ||
NCT04089189 | Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer | Phase 2 Interventional | Impact Therapeutics, Inc. | ||
NCT04169997 | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | Phase 3 Interventional | Impact Therapeutics, Inc. |